Related Experiment Video
Updated: Mar 28, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
The dilemma of thromboprophylaxis in stroke patients
Shiksha Guru1, Adrian Parry-Jones2, Jecko Thachil3
1University of Manchester, Manchester, UK.
Acute stroke is one of the leading causes of mortality worldwide, with venous thromboembolism (VTE) representing a significant yet under-recognised complication. The risk of VTE is highest in the early post-stroke period, driven by factors encapsulated by Virchow's triad. However, the risk of haemorrhagic transformation following ischaemic stroke, and haematoma development and expansion after haemorrhagic stroke complicate the routine use of pharmacological VTE prophylaxis. In this review, we discuss the epidemiology and aetiology of VTE post-stroke, haemorrhagic transformation after acute ischaemic events, and the available evidence supporting mechanical and pharmacological approaches to VTE prophylaxis in these patients. Finally, we discuss the recommendations provided by the current international consensus guidelines and reasons underpinning the heterogeneous management of patients in routine clinical practice, including the need for well-designed, large-scale clinical trials to better define thromboprophylaxis strategies for patients following acute stroke.
Acute stroke is one of the leading causes of mortality worldwide, with venous thromboembolism (VTE) representing a significant yet under-recognised complication. The risk of VTE is highest in the early post-stroke period, driven by factors encapsulated by Virchow's triad. However, the risk of haemorrhagic transformation following ischaemic stroke, and haematoma development and expansion after haemorrhagic stroke complicate the routine use of pharmacological VTE prophylaxis. In this review, we discuss the epidemiology and aetiology of VTE post-stroke, haemorrhagic transformation after acute ischaemic events, and the available evidence supporting mechanical and pharmacological approaches to VTE prophylaxis in these patients. Finally, we discuss the recommendations provided by the current international consensus guidelines and reasons underpinning the heterogeneous management of patients in routine clinical practice, including the need for well-designed, large-scale clinical trials to better define thromboprophylaxis strategies for patients following acute stroke.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

